Your DNA might hold vital information that your doctor overlooks when prescribing treatments.
A recent publication in Science Translational Medicine revealed that almost 25% of participants were given medications that could have been substituted with alternatives or adjusted in dosage based on their genetic profiles.
Conducted by researchers from the University of Pittsburgh, the study focused on 16 genes that influence how individuals metabolize drugs.
The research analyzed DNA samples from 98,590 individuals enrolled in the National Institutes of Health’s All of Us Research Program, correlating the genetic data with available medical records.
Every participant exhibited at least one significant genetic variation that could alter their reaction to specific medications, with an average of nine variations per person. Among those with both genetic and clinical information, 24.4% had received at least one medication that, according to genetic guidelines, should have been changed to another drug or prescribed at a different dosage.
Nonetheless, the study did not assess whether patients suffered from side effects or if their medications were less effective due to their genetic profiles.
Dr. Philip Empey, an associate professor at the University of Pittsburgh School of Pharmacy and the study’s senior author, stated that understanding a patient’s genetic information could minimize the trial-and-error approach often seen in medical treatment.
“Anything we can do to better predict the optimal medications and dosages from the start can significantly reduce that trial-and-error process,” he noted.

A pharmacist organizes medications in a Vancouver pharmacy in October 2022. Genetic differences can influence how patients react to certain drugs, which may necessitate dosage adjustments or alternative prescriptions. (Darryl Dyck/The Canadian Press)
Identifying the right medication
Among the most frequently prescribed drugs to participants with genetic profiles indicating treatment modification were omeprazole and pantoprazole for acid reflux, as well as atorvastatin for cholesterol management.
Empey pointed out that certain genetic variations can heighten the risk of muscle-related issues when patients take statins like atorvastatin, which aim to lower the likelihood of heart attacks or strokes.
This insight could enable healthcare providers to opt for different medications or modify their treatment plans.
“It empowers clinicians to make more informed decisions, such as, ‘Perhaps that cholesterol medication isn’t suitable. Maybe we should start with a lower dose or monitor for specific side effects more closely,'” Empey explained.
For certain drugs, the implications can be quite severe.
For instance, specialists consulted by CBC News indicate that genetic testing can pinpoint patients unlikely to benefit from clopidogrel (Plavix), a medication used to prevent blood clots post-cardiac stenting, enabling physicians to switch them to a different therapy.

Dr. James Kennedy leads the Tanenbaum Centre for Pharmacogenetics at the Centre for Addiction and Mental Health in Toronto. He emphasizes that while genetic testing aids in medication selection, factors like diet, lifestyle, and existing medications must also be taken into account. (CBC)
A guide, not a certainty
Dr. James Kennedy noted that the findings of the study were expected, but he was particularly impressed by the genetic diversity and representation of individuals of African descent.
Kennedy’s team has conducted genetic testing for around 11,000 patients, many of whom had previously tried two to three antidepressants without achieving satisfactory outcomes.
He mentioned that about 8 to 10 percent of individuals metabolize certain commonly prescribed antidepressants at a much slower rate, leading to medication buildup and potential side effects.
Kennedy believes that genetic testing is particularly beneficial for patients who have had difficulties with multiple medications.
However, he cautioned that genetic testing alone cannot fully predict a patient’s response to a specific medication. Other factors, such as concurrent medications, smoking habits, and dietary choices, also need consideration.
“We say, ‘Here’s your genetic profile, here are some tendencies, and now we need to discuss all the other variables that will influence the final decision,'” he remarked.
A 2023 clinical trial in Europe mentioned in the study found that conducting genetic tests prior to prescribing specific medications reduced adverse drug reactions. However, implementing routine testing in Canada remains a challenge.

A researcher at the University of Calgary demonstrates a diagnostic kit used for identifying genetic variations in February 2024. While such testing could enable tailored medication for patients, the costs and practical challenges have hindered its widespread adoption across Canada. (Jeff McIntosh/The Canadian Press)
Challenges in Canada for widespread testing
Dr. Jacob Udell, a cardiologist in Toronto, remarked on the impressive nature of the study, particularly its participant genetic diversity, yet noted that few healthcare providers in Canada or the U.S. routinely assess patients for genetic variations related to drug metabolism.
“This is not typically on the radar for front-line clinicians,” he stated.
Udell explained that for many conditions, doctors can prescribe a medication, observe the patient’s response, and adjust as needed, often without serious repercussions. This method can be more feasible than universally screening for genetic variations.
He also questioned the necessity of widespread testing as a priority when Canada’s healthcare system faces challenges in providing basic services.
“We are focused on ensuring everyone has access to a family doctor,” he remarked.
Beyond the test costs, Udell indicated that healthcare providers would also need access to genetic test results and the expertise to interpret them accurately.
Empey concurred, stating that making genetic testing standard practice would require substantial investment in training, infrastructure, and new systems for sharing results among healthcare providers.
“The scientific rationale is compelling for many medications. The implementation question becomes more about economics, processes, and education,” he explained.
Currently, Empey advises patients to consult their doctors or pharmacists about the potential benefits of genetic testing and to share any relevant results.
Udell cautioned that private testing may become increasingly accessible for those who can afford it, “but that will not assist those who cannot cover the costs of testing.”
